Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis
Recruiting
Phase 2
Interventional Study
Demodex Blepharitis
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 250 (estimated)
- Sponsor
- Glaukos Corporation · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a randomized, double-masked, placebo-controlled, dose-ranging, parallel-group, multi-center study designed to evaluate the safety and efficacy of GLK-321 in patients with Demodex blepharitis.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Signs of Demodex blepharitis in at least one eye
* Best Spectacle Corrected Visual Acuity (BSCVA) of 20/80 Snellen or better in each eye
Exclusion Criteria:
* Presence of eczema or dermatitis in the ocular region of either eye
* Use of lid hygiene products within 14 days of …
Contacts